Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Dec 06, 2020 11:24am
173 Views
Post# 32045945

RE:RE:Big Competition is ON

RE:RE:Big Competition is ON

Agreed. The liquid biopsy space is huge. Stage will be the first to market.  Even if it wasn't we would be a prime candidate for a buyout of a large pharma or healthcare company wanting to get in.  

It's a win win that just needs Aristotle rolled out    


can't wait for the conference call and update.  Did I hear it was Tuesday pre market?



ScienceFirst wrote: I feel sad for OldAnus007.  He's all mixed up.  Unable to assess what Grail still has to do.  Simply pathetic. 

Funny, competition is not even an issue to me as all big players that don't have a liquid biopsy platform will want to jump in that lucrative 73B$ market.  And that will only favor those that have one, like us.  SLSZ is already building its network (large healtcare group, groups of clinics, etc ...).  That will continue to grow until the launch, which will then bring us growing number of revenues.

 

<< Previous
Bullboard Posts
Next >>